The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://janazrxb759836.wikistatement.com/5347770/glp_3_retatrutide_a_comparative_analysis